摘要
目的探讨胸苷酸合成酶(TS)和核糖核苷酸还原酶M1(RRM1)的表达与培美曲塞或吉西他滨联合卡铂治疗晚期非鳞非小细胞肺癌疗效的关系。方法晚期非鳞非小细胞肺癌患者70例,分为培美曲塞+卡铂化疗组35例及吉西他滨+卡铂治疗组35例,检测培美曲塞+卡铂化疗组患者肺癌组织TS的水平和吉西他滨+卡铂化疗组患者肺癌组织RRM1的水平,分析客观缓解率(ORR)、无进展生存时间(PFS)与TS、RRM1水平的关系。结果培美曲塞+卡铂化疗组中TS高表达患者ORR为15.8%(3/19),低于TS低表达患者的75.0%(12/16)(P<0.05);TS高表达患者PFS为(2.1±0.6)个月,短于TS低表达患者的(6.6±2.1)个月(P<0.05)。吉西他滨+卡铂化疗组RRM1高表达患者ORR为17.6%(3/17),低于RRM1低表达患者ORR的72.2%(13/18)(P<0.05);RRM1高表达患者PFS为(2.2±0.6)个月,短于RRM1低表达患者的PFS(7.1±3.4)个月(P<0.05)。结论晚期非鳞非小细胞肺癌患者采用培美曲塞联合卡铂化疗时,TS低表达者的临床疗效较好,而采用吉西他滨联合卡铂化疗时,RRM1低表达者的临床疗效较好。
Objective To explore the relationship of thymidylate synthase（ TS） and ribonucleotide reductase Ml（ RRM1） expressions with efficacy of pemetrexed or gemcitabine combined with carboplatin for the treatment of advanced non-squamous non-small cell lung cancer.Methods Seventy patients with advanced non-squamous non-small cell lung cancer were divided into pemetrexed ＋ carboplatin group（ n = 35）and gemcitabine ＋ carboplatin group（ n = 35）. The expression level of TS in lung cancer tissues was detected in the pemetrexed ＋ carboplatin group,and the expression level of RRM1 in lung cancer tissues was detected in the gemcitabine ＋ carboplatin group. The relationship of objective response rate（ ORR） or progression-free survival（ PFS） with TS and RRM1 expression levels was analyzed. Results In pemetrexed ＋ carboplatin group,the ORR of patients with high TS expression levels was lower than that of patients with low TS expression levels[15. 8%（ 3 /19） vs.75. 0%（ 12 /16）,P〈0. 05]; the PFS of patients with high TS expression levels was less than that of patients with low TS expression levels[（ 2. 1 ± 0. 6） months vs.（ 6. 6 ± 2. 1） months,P〈0. 05]. In the gemcitabine ＋ carboplatin group,the ORR of patients with high RRM1 expression levels was lower than that of patients with low TS expression levels[（ 17. 6%（ 3 /17） vs. 72. 2%（ 13 /18）,P〈0. 05]; the PFS of patients with high RRM1 expression levels was less than that of patients with low RRM1 expression levels[（ 2. 2 ± 0. 6） months vs.（ 7. 1 ± 3. 4）months,P〈0. 05]. Conclusion For patients with advanced non-squamous non-small cell lung cancer,the patients with low TS expression levels have superior efficacy when receiving the chemotherapy of pemetrexed and carboplatin,whereas the patients with low RRMI expression levels have superior efficacy when receiving the chemotherapy of gemcitabine and carboplatin.
出处
《广西医学》
CAS
2016年第7期945-947,952,共4页
Guangxi Medical Journal
基金
广东省东莞市医疗卫生科技计划项目(201110515001105)
关键词
非鳞非小细胞肺癌
晚期
胸苷酸合成酶
核糖核苷酸还原酶M1
培美曲塞
吉西他滨
卡铂
客观缓解率
无进展生存时间
Non-squamous non-small cell lung cancer
Advanced
Thymidylate synthase
Ribonucleotide reductase M1
Pemetrexed
Gemcitabine
Carboplatin
Objective response rate
Progression-free survival
